Dyne Therapeutics【DYN】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

14.29

買値

13.57

売値

14.50

出来高

976,223

13.76 日の範囲 14.50

13.07 52 週間の範囲 47.45

時価総額

1.454B

前日終値

14.05

始値

14.22

時刻

13.69

最終取引時間

財務取引量

US$ 13,639,196

VWAP

13.9714

平均取引量 (3 か月)

1,743,097

発行済株式数

101,765,958

配当利回り

PER

-6.00

1 株当たり利益 (EPS)

-2.32

歳入

純利益

-235.94M

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.dyne-tx.com

本社

Wilmington, Delaware, USA

設立

Dyne Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker DYN. The last closing price for Dyne Therapeutics was US$14.05. Over the last year, Dyne Therapeutics shares have traded in a share price range of US$ 13.07 to US$ 47.45.

Dyne Therapeutics currently has 101,765,958 shares in issue. The market capitalisation of Dyne Therapeutics is US$1.43 billion. Dyne Therapeutics has a price to earnings ratio (PE ratio) of -6.00.

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and...

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025...

Form 8-K - Current report

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101

- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with...

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-2.22	-13.4463961236	16.51	16.64	13.07	1346634	14.2100283	CS
4	-0.6	-4.02955003358	14.89	17.175	13.07	2542144	14.21962491	CS
12	-15.285	-51.6821639899	29.575	31.32	13.07	1743097	18.08153276	CS
26	-29.6	-67.4413305992	43.89	47.45	13.07	1454266	25.85705422	CS
52	-9.31	-39.4491525424	23.6	47.45	13.07	1354114	28.27322287	CS
156	7.28	103.851640514	7.01	47.45	4.3	796375	21.77375596	CS
260	-9.16	-39.0618336887	23.45	47.45	4.3	631632	21.1620744	CS

DYN - Frequently Asked Questions (FAQ)

What is the current Dyne Therapeutics share price?

The current share price of Dyne Therapeutics is US$ 14.29

How many Dyne Therapeutics shares are in issue?

Dyne Therapeutics has 101,765,958 shares in issue

What is the market cap of Dyne Therapeutics?

The market capitalisation of Dyne Therapeutics is USD 1.43B

What is the 1 year trading range for Dyne Therapeutics share price?

Dyne Therapeutics has traded in the range of US$ 13.07 to US$ 47.45 during the past year

What is the PE ratio of Dyne Therapeutics?

The price to earnings ratio of Dyne Therapeutics is -6

What is the reporting currency for Dyne Therapeutics?

Dyne Therapeutics reports financial results in USD

What is the latest annual profit for Dyne Therapeutics?

The latest annual profit of Dyne Therapeutics is USD -235.94M

What is the registered address of Dyne Therapeutics?

The registered address for Dyne Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Dyne Therapeutics website address?

The website address for Dyne Therapeutics is www.dyne-tx.com

Which industry sector does Dyne Therapeutics operate in?

Dyne Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
JTAIJet AI Inc	US$ 6.02 (133.33%)	101.64M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	248.48M
WRDWeRide Inc	US$ 31.4877 (83.39%)	20.57M
INLFINLIF Limited	US$ 16.27 (80.58%)	7.67M
MBRXMoleculin Biotech Inc	US$ 2.1201 (66.94%)	134.88M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3.08 (-56.31%)	430.77k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	US$ 19.0001 (-49.58%)	1.03M
NEXNNexxen International Ltd	US$ 10.30 (-49.16%)	164.82k
BSLKBolt Projects Holdings Inc	US$ 0.6626 (-46.13%)	13.4M
CNSPCNS Pharmaceuticals Inc	US$ 0.1415 (31.26%)	489.28M
MGOLMGO Global Inc	US$ 0.7176 (-15.08%)	417.31M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
INTCIntel Corporation	US$ 23.60 (-2.20%)	230.26M
NVDANVIDIA Corporation	US$ 138.85 (2.63%)	194.99M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Dyne Therapeutics Inc (DYN) 銘柄情報

Dyne Therapeutics Inc (DYN)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Dyne Therapeutics Inc について

DYN 最新ニュース

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Form 8-K - Current report

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Form 8-K - Current report

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

DYN - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する